Assistant Professor of Medicine
Specialty Areas: Glomerular disease, vasculitis (primary focus: ANCA vasculitis), lupus nephritis, drug-induced autoimmune disease.
BA: University of North Carolina at Chapel Hill, 1997
PhD: Molecular and Cellular Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 2003
MD: University of North Carolina School of Medicine, 2008
Residency: Categorical Internal Medicine, University of California, San Francisco, 2010
Fellowship: Joint Nephrology Fellowship Program, Brigham and Women’s Hospital and Massachusetts General Hospital, 2013
Visiting Postdoctoral Scholar: The Broad Institute of Harvard and MIT, 2011-present
Assistant Professor of Medicine: University of North Carolina, 2013-present
Board Certifications: Internal Medicine and Nephrology
Dr. Pendergraft’s professional mission is to:
- Provide world-renowned expert medical care for patients with kidney disease
- Educate and excite trainees about nephrology
- Conduct translational and clinical research in order to cure autoimmune disease and prevent relapse with a special emphasis on autoimmune diseases that affect the kidneys
Currently, Dr. Pendergraft’s research program includes:
- Understanding response to therapy and relapse in lupus nephritis and ANCA vasculitis using high-resolution systems-level tools (epigenetic, transcriptomic, metabolomic, proteomic and microbiomic)
- Repurposing FDA-approved drugs for use in lupus nephritis and ANCA vasculitis
- Translational studies aimed at understanding drug-induced forms of ANCA vasculitis
- Clinical trials of existing and novel biologic therapies for lupus nephritis and ANCA vasculitis
- Clinical data analysis of large and unique cohorts of patients with either lupus nephritis, ANCA vasculitis or idiopathic membranous nephropathy
- In-depth characterization of rituximab use and development of guidelines to prevent and manage adverse events
- Pendergraft, W.F., Niles, J.L. “Trojan horses: drug culprits associated with anti-neutrophil cytoplasmic autoantibody vasculitis.” Current Opinion in Rheumatology, 26(1): 42-49, January 2014.
- Ramirez-Ortiz, Z.G., Pendergraft, W.F., Prasad, A., Byrne, M.H., Iram, T., Blanchette, C.J., Luster, A.D., Hacohen, N., Khoury, J.E., Means, T.K. “The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity.” Nature Immunology, 14(9): 917-26, September 2013.
- Pendergraft, W.F., McGrath, M.M., Murphy, A.P., Murphy, P., Laliberte, K.A., Greene, M.F., Niles, J.L. “Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.” Annals of the Rheumatic Diseases, 72(12): 2051-3, December 2013.
- Arazi, A., Pendergraft, W.F., Ribeiro, R.M., Perelson, A.S., Hacohen, N. “Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.” Seminars in Immunology, 25(3): 193-200, October 2013.
- Ciavatta, D.J., Yang, J.J., Preston, G.A., Badhwar, A.K., Xiao, H., Hewins, P., Nester, C.M., Pendergraft, W.F., Magnuson, T.R., Jennette, J.C., Falk, R.J. “Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.” Journal of Clinical Investigation, 120(9): 3209-19, September 2010.
- Pendergraft, W.F., Pressler, B.M., Jennette, J.C., Falk, R.J., Preston, G.A. “Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.” Journal of Molecular Medicine, Vol. 83(1): 12-25, January 2005.
- Pendergraft, W.F., Preston, G.A., Shah, R.R., Tropsha, A., Carter, C., Jennette, J.C., Falk, R.J. “ Autoimmunity is triggered by cPR-3(105-201), a protein complementary to the human autoantigen Proteinase-3.” Nature Medicine, Vol. 10(1): 72-79, January 2004.
- Pendergraft, W.F., Rudolph, E.H., Falk, R.J., Jahn, J.E., Grimmler, M., Hengst, L., Jennette, J.C., Preston, G.A. “Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis.” Kidney International, Vol. 65(1): 75-84, January 2004.
- Pendergraft, W.F., Alcorta, D.A., Segelmark, M., Yang, J.J., Tuttle, R., Jennette, J.C., Falk, R.J., Preston, G.A. “ANCA antigens, proteinase 3 (PR3) and myeloperoxidase (MPO), are not expressed in endothelial cells.” Kidney International, Vol. 57(5): 1981-1990, May 2000.